


PHARMACEUTICAL 2023

Gain Therapeutics Inc. Rank 211 of 446









Gain Therapeutics Inc. Rank 211 of 446



The relative strengths and weaknesses of Gain Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Gain Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Gain Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 102%, being 58% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	21,091
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,125
Liabilities, Non-Current	1,095
Other Assets	2,864
Other Compr. Net Income	0
Other Expenses	93
Other Liabilities	0
Other Net Income	279
Other Revenues	140
Property and Equipment	144
Research and Development	8,377
Selling, General and Administrative Expense	9,540

Output Variable	Value in 1000 USD
Assets	24,099
Liabilities	5,220
Expenses	18,010
Revenues	140
Stockholders Equity	18,880
Net Income	-17,591
Comprehensive Net Income	-17,591
Economic Capital Ratio	102%

